TEDA BIOMEDICAL (08189) issues a profit warning, expecting an annual net loss of about 85 million yuan for shareholders.
Teda Biotech (08189) announced that the group expects to record a net loss attributable to shareholders of approximately RMB 85 million for the year ending December 31, 2025, while the net loss attributable to shareholders for the year ending December 31, 2024 was RMB 27.8022 million.
TEDA BIOMEDICAL (08189) announced that the group is expected to record a net loss attributable to shareholders of approximately 85 million yuan for the year ending December 31, 2025, while the net loss attributable to shareholders for the year ending December 31, 2024 was 27.8022 million yuan.
Related Articles
New Stock News | Aqara International Ltd. Submits Application to Hong Kong Stock Exchange
TOP SPRING (03688) issues profit warning, expecting a net loss of HKD 3 billion for the year 2025.
Hansoh Pharma (03692) released its annual performance with a net profit attributable to shareholders of 5.55 billion yuan, representing a year-on-year increase of 27.07%.
New Stock News | Aqara International Ltd. Submits Application to Hong Kong Stock Exchange
TOP SPRING (03688) issues profit warning, expecting a net loss of HKD 3 billion for the year 2025.
Hansoh Pharma (03692) released its annual performance with a net profit attributable to shareholders of 5.55 billion yuan, representing a year-on-year increase of 27.07%.
RECOMMEND
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026
